CG Oncology
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +48.8% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | -15.0% | Better than 1% |
| Operating margin | -4,722.1% | Better than 1% |
| Net margin | -3,985.0% | Better than 1% |
| Return on equity | -21.7% | Better than 16% |
| Return on invested capital | -25.6% | Better than 11% |
Momentum A
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -0.4% | Better than 73% |
| 6-month return | 23.7% | Better than 86% |
| 12-month return (ex latest month) | 45.4% | Better than 81% |
| Distance below 52-week high | 15.4% | Better than 70% |
Financial Health A-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 24.6x | Better than 99% |
| Debt to assets | 0.9% | Better than 93% |
| Interest coverage | -35,442.0x | Better than 0% |
Analyst View B-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 13.3% | Better than 19% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 81.90
- Open
- 80.32
- Day range
- 79.21 - 83.16
- Avg price
- 80.74
- Volume
- 1.67M
- Turnover
- 135.18M
- Turnover ratei
- 2.43%
- Volume ratioi
- 0.40
- Amplitudei
- 4.82%
- 52-week rangei
- 37.01 - 93.95
Valuation
- P/Ei
- -38.21
- P/E (TTM)i
- -28.79
- P/Bi
- 7.16
- EPSi
- -2.08
- Book value / shi
- 11.10
- Net profit
- -185.78M
- Net assets
- 990.99M
Share structure
- Market cap
- 7.10B
- Float capi
- 5.48B
- Shares out
- 89.32M
- Float sharesi
- 68.95M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2024-01-25
15.4% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-22.27M net over the window
Short interest
- Shares short
- 9.22M
- % of floati
- 10.40%
- Days to coveri
- 10.96
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of CG Oncology (CGON)?
CG Oncology last traded at 79.47. This page shows a periodic quote snapshot. Check the displayed quote time.
What is CG Oncology's market cap?
About 7.10B.
What is the P/E ratio of CG Oncology?
The trailing twelve-month P/E is -28.79. The Valuation tab shows it against the stock's own five-year range.
Does CG Oncology pay a dividend?
CG Oncology does not currently pay a regular dividend.
Is CG Oncology a buy according to analysts?
The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 90.00, which implies 13.3% upside from the current price. This is not investment advice.
What is CG Oncology's StockVane Quant Rating?
The StockVane Momentum strategy currently rates CG Oncology a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 20:02:23 · For reference only, not investment advice and not tailored to your situation.
CG Oncology discussion 0 comments